W

William Osler Health System | Brampton Civic Hospital - Oncology Department

Research site
(Unclaimed)
Location
2100, Bovaird Drive East, Brampton, Ontario, Canada
Site insights

Top conditions

Non-Small-Cell Lung Carcinoma (6 trials)

COVID-19 (5 trials)

Lung Cancer (5 trials)

Cancer (2 trials)

Colorectal Cancer (1 trial)

Top treatments

Pembrolizumab
Cyclophosphamide
Tocilizumab
Inupadenant
Moxifloxacin
Fulvestrant
Piperacillin
EOS100850
ritonavir
Amoxicillin-clavulanate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

14 of 32
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis (MAESTRO-NASH)

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

COVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response....

Enrolling
COVID-19
ARDS
Other: SOC plus Placebo IV
Biological: SOC plus 15mg/kg EB05 IV

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with ep...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Lazertinib
Drug: Amivantamab

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the t...

Enrolling
Metastatic Colorectal Cancer
Biological: Pembrolizumab
Biological: Cetuximab

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Rituximab

One of the most important obstacles to improving end-of-life care is the inability of clinicians to reliably identify those who are approaching the e...

Invitation-only
Implementation Science
Screening
Other: modified Hospital One-year Mortality Risk (mHOMR)

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therap...

Enrolling
Breast Cancer
Drug: Fulvestrant
Drug: Ipatasertib

This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line t...

Enrolling
Non-Small Cell Lung Cancer
Drug: Platinum + Pemetrexed Chemotherapy Second-Line
Drug: Osimertinib First-Line

This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced an...

Active, not recruiting
Bladder Cancer
Microsatellite Instability-High
Drug: Pembrolizumab
Drug: Cyclophosphamide

Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed...

Enrolling
Stage III NSCLC
Metastatic NSCLC
Drug: Pemetrexed
Drug: inupadenant

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors...

Active, not recruiting
Breast Cancer
Locally Advanced Solid Tumor
Drug: Seribantumab

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

Active, not recruiting
Loss of Appetite
Non-small Cell Lung Cancer
Drug: Placebo for ponsegromab
Drug: ponsegromab

The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants...

Active, not recruiting
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Drug: Cisplatin
Drug: Pemetrexed

Trial sponsors

Pfizer logo

Pfizer (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems